

Reference: FOI.ICB-2627/103

Subject: Hereditary Angioedema (HAE) High-cost-drug (Blueteq) Approvals

I can confirm that the ICB does not hold the information requested; please see responses below:

QUESTION	RESPONSE
Under the Freedom of Information Act 2000, in your role commissioning specialised immunology services (delegated from April 2025), please provide aggregate counts only (standard suppression accepted):	
1. The number of Blueteq / high-cost-drug prior approvals in force for hereditary angioedema long-term prophylaxis, by medicine (Ianadelumab, berotralstat, garadacimab, plasma-derived C1-INH), for each month/quarter from January 2023 to the latest available. 2. Where recorded, these counts by patient ICB of residence / responsible commissioner. 3. The provider(s) through which these patients are managed (e.g. which specialist centre), so cross-boundary flow can be understood.	The ICB does not hold this information. The ICB is not the commissioner of specialised immunology services, this is NHS England Specialised Commissioning. Please contact NHS England directly for this information: https://www.england.nhs.uk/contact-us/foi/

The information provided in this response is accurate as of 11 June 2026 and has been approved for release by Dr Geeta Iyer, Deputy Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.